Skip to content

GDPoster

Breast Cancer Drugs May Severely Inflame Lungs, FDA Warns

    The US Food and Drug Administration (FDA) issued a warning today that the commonly prescribed breast cancer therapies known as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors may cause rare but severe inflammation of the lungs. The related products include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Eli Lilly), which are approved for use in patients with hormone receptor (HR)-positive, human epidermal… Read More »Breast Cancer Drugs May Severely Inflame Lungs, FDA Warns

    FDA OKs Istradefylline for Parkinson’s Disease ‘Off’ Episodes

      The US Food and Drug Administration (FDA) has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease (PD) experiencing “off” episodes. Istradefylline is a selective adenosine A2A receptor antagonist. Its effectiveness in treating “off” episodes in patients with PD taking levodopa/carbidopa was shown in four 12-week, placebo-controlled clinical studies that included a total of 1143 participants.… Read More »FDA OKs Istradefylline for Parkinson’s Disease ‘Off’ Episodes

      Stage Set for Big Measles Outbreaks in Texas With Current Vaccination Rates

        Current Texas schools’ vaccination rates could allow for measles outbreaks as large as 400 cases in the Dallas-Fort Worth and Austin metropolitan areas. Even slight decreases in immunization rates could result in exponentially larger outbreaks, the authors say, noting that other states have population centers at similar risk. “Lower vaccination rates imply that outbreaks may… Read More »Stage Set for Big Measles Outbreaks in Texas With Current Vaccination Rates

        FDA Approves Drug Trio for UTI, Intra-abdominal Infection

          The US Food and Drug Administration (FDA) has approved the antibacterial drug trio imipenem, cilastatin, and relebactam (Recarbrio, Merck) for complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in adults for whom “limited or no treatment options are available.” “Recarbrio provides an important addition to our toolkit in the ongoing fight against infections caused… Read More »FDA Approves Drug Trio for UTI, Intra-abdominal Infection

          Dual Therapy for HIV Two-Stepping In

            Two-drug regimens may be as effective and safe as multi-drug therapies, according to investigators evaluating paired down treatment options for HIV. “I don’t mean to say that everyone should be on dual therapy,” but it could be the beginning of a new era in HIV treatment, said Pedro Cahn, MD, from the Buenos Aires University Medical… Read More »Dual Therapy for HIV Two-Stepping In